ENABLEX Drug Patent Profile

When do Enablex patents expire, and when can generic versions of Enablex launch?

Enablex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in ENABLEX is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Enablex

A generic version of ENABLEX was approved as darifenacin hydrobromide by CIPLA on September 1^st, 2016.

Summary for ENABLEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	16
Patent Applications:	262
Drug Prices:	Drug price information for ENABLEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ENABLEX
What excipients (inactive ingredients) are in ENABLEX?	ENABLEX excipients list
DailyMed Link:	ENABLEX at DailyMed

See drug prices for ENABLEX

Recent Clinical Trials for ENABLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Scientific & Medical Affairs, Inc.
Universidad de Valparaiso	Phase 3
Recalcine (GynoPharm)	Phase 3

See all ENABLEX clinical trials

Paragraph IV (Patent) Challenges for ENABLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENABLEX	Extended-release Tablets	darifenacin hydrobromide	7.5 mg and 15 mg	021513	3	2008-12-22

US Patents and Regulatory Information for ENABLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004		DISCN	Yes	No
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004		DISCN	Yes	No

Expired US Patents for ENABLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004	5,096,890
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004	6,106,864
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-002	Dec 22, 2004	5,096,890
Abbvie	ENABLEX	darifenacin hydrobromide	TABLET, EXTENDED RELEASE;ORAL	021513-001	Dec 22, 2004	6,106,864

EU/EMA Drug Approvals for ENABLEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
pharmaand GmbH	Emselex	darifenacin hydrobromide	EMEA/H/C/000554Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.	Authorised	no	no	no	2004-10-22

International Patents for ENABLEX

See the table below for patents covering ENABLEX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	96783
Australia	5140290
Australia	614224
Bosnia and Herzegovina	98300
Canada	2012295	DERIVES DE LA PYRROLIDINE (PYRROLIDINE DERIVATIVES)

Supplementary Protection Certificates for ENABLEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0850059	CA 2005 00020	Denmark
0850059	91163	Luxembourg		91163, EXPIRES: 20191022
0850059	300190	Netherlands		300190, 20160821, EXPIRES: 20191021
0850059	SPC012/2005	Ireland		SPC012/2005, 20060725, EXPIRES: 20191021
0850059	C00850059/01	Switzerland		FORMER OWNER: NOVARTIS AG, CH

Enablex (darifenacin) Market Dynamics and Financial Trajectory: Exclusivity Timelines, Generic/Biosimilar Risk, and Competitive Landscape

Last updated: June 19, 2026

Enablex (darifenacin), an oral antimuscarinic for overactive bladder, is mature and largely exposed to generic competition. Its commercial trajectory is shaped by (1) loss of branded exclusivity in the US, (2) widening price competition for antimuscarinics, and (3) shifting prescriber and payer preferences toward β3-adrenergic agonists and other bladder therapies. The result is a steady brand erosion pattern typical of off-patent small-molecule chronic-care drugs.

What patents protect Enablex (darifenacin) and how strong is the patent estate?

Core answer: The US patent estate for darifenacin is largely off-term for marketed products, with remaining value concentrated in narrower formulation, manufacturing, and line-extension patents rather than broad compound claims.

Which patent families cover darifenacin oral dosing and specific formulations?

• Darifenacin was granted early composition-of-matter coverage tied to the drug substance.
• For branded products, later protection typically shifts to:
  • solid-state or formulation patents (tablet composition, coating, excipients, release characteristics)
  • process/method-of-manufacture patents
  • packaging and dosage-unit related claims, where applicable
• As brand exclusivity expires, these narrower patents usually provide limited leverage against true generics unless an approval-relevant claim is asserted (for example, a specific formulation or manufacturing method required by the generic).

Key patent estate pattern for off-patent oral antimuscarinics

• Early compound patents drive exclusivity and initial market capture.
• After expirations, the remaining enforcement posture is usually:
  • selective infringement theories
  • settlement leverage tied to launch timing
  • geographic or product-specific constraints

When does Enablex lose exclusivity and what are the patent expiration dates?

Core answer: Enablex’s practical exclusivity window in the US has already passed; remaining branded value depends on residual exclusivity (if any) and then primarily on labeling, brand recognition, and payer contracting rather than patent-driven barriers.

How exclusivity timelines typically unfold for darifenacin brands

• Composition-of-matter expiry is the main driver of generic entry risk.
• Any later exclusivity (for example, formulation or method-of-use) is usually narrower and shorter.
• Once generic approvals begin, brand revenue usually transitions quickly to low-single-digit market share and price suppression dynamics.

What is the Orange Book status of Enablex (darifenacin)?

Core answer: Enablex is an approved NDA product that is not protected by current, broad, enforceable exclusivity that would block standard generic entry in the US; the Orange Book listing is consistent with a mature product lifecycle.

How to interpret Orange Book listings in a mature antimuscarinic category

• If Orange Book listings show primarily expired patents or patents that do not align with approval-relevant generic requirements, the brand’s IP moat is limited.
• If any listed patents remain, the risk posture depends on whether a generic can design around them and whether a Paragraph IV challenge is viable.

What generic entry risks exist for Enablex (darifenacin)?

Core answer: Generic entry risk is structurally high because darifenacin is a small-molecule drug with straightforward oral solid dosage manufacturing, and the long lead-time patent barriers have already lapsed.

What do Paragraph IV challenges imply in this product category?

• Paragraph IV filings target specific listed patents and often lead to:
  • automatic 30-month stays (when applicable)
  • settlement agreements that move generic launch earlier or later than the default date
• With mature products, the market effect is usually rapid price erosion once first generics launch.

What is the generic competitive effect in overactive bladder antimuscarinics?

• Price compression is typically steep when multiple generics enter.
• Brand retention depends on:
  • payer formularies
  • copay design
  • physician familiarity
  • switching inertia for chronic dosing

What FDA regulatory status does Enablex have and how does that affect competition?

Core answer: Enablex is an FDA-approved small-molecule oral drug under established labeling for overactive bladder symptoms. That status reduces regulatory friction for generics compared with newer biologics or complex delivery systems.

What FDA pathways typically dominate for darifenacin generics

• Generic applicants generally use ANDA pathways for an approved reference listed drug.
• Once reference product exclusivity is expired and listed patents do not block approval, generic pathways accelerate.

How does Enablex compare with competing overactive bladder drugs on market dynamics?

Core answer: Enablex faces competitive pressure from:

• β3-adrenergic agonists (preferred by many payers for efficacy/tolerability profiles)
• alternative antimuscarinics
• combination and newer symptom-management strategies

Why market share shifts away from antimuscarinics

• Payer policies increasingly favor therapies with favorable tolerability.
• Patients may prefer options with lower anticholinergic side-effect burden.
• Evidence syntheses and guideline updates often influence formulary placement.

How do settlement agreements and litigation affect Enablex launch timing?

Core answer: For mature small molecules, the key driver is whether prior disputes resulted in delayed generic launches; after multiple generic entrants, incremental legal leverage usually declines.

What settlement dynamics are typical for legacy overactive bladder brands

• First generic entrants may be delayed via settlement.
• Subsequent generics often launch in succession once a workable patent landscape is established.
• Post-settlement market outcomes become dominated by price, rebates, and formulary placement.

Revenue exposure: how much cash flow is at risk for Enablex as competition increases?

Core answer: With broad generic availability already established, brand revenue exposure is mainly to:

• continued formulary displacement
• rebate compression and net price erosion
• pharmacy channel switching to lowest WAC/AWP-linked options

Commercial trajectory patterns for off-patent oral chronic brands

• Early peak post-launch, then:
  • gradual share erosion during pre-generic erosion window
  • sharp margin pressure at first generic entry
  • sustained low-margin existence after multiple generics
• The remaining value is usually in:
  • contracted access
  • brand-specific patient subsets
  • historical prescriber behavior

What manufacturing and IP barriers could slow generic substitution for Enablex?

Core answer: For oral solid darifenacin, manufacturing complexity is moderate. True barriers depend on:

• formulation-specific properties that must be replicated for bioequivalence
• any remaining, approval-relevant patents (if still active)
• potential method patents tied to scale-up processes

What determines bioequivalence and switchability

• Release profile and solubility-related performance
• Particle size and excipient selection to meet dissolution targets
• Stability and shelf-life compliance

Key market dynamics specific to overactive bladder

Core answer: Overactive bladder is a crowded chronic category where payer and guideline evolution drives fast switching once generics are available and where newer mechanisms gain preference.

Payer and formulary mechanics that shape Enablex sales

• Tier placement changes quickly after generics enter.
• Net pricing is impacted more by rebate structures than by wholesale pricing.
• Step edits and prior authorizations are more common for newer agents and high-cost products; for generics, placement is frequently automatic.

Prescriber and patient behavior

• Switches from a branded antimuscarinic can be incremental but become easier when:
  • generics have stable performance
  • side-effect concerns are manageable
  • patients remain symptom-controlled

Competitor landscape: which drug classes most directly pressure Enablex?

Core answer: The most direct competitive pressure comes from:

• other antimuscarinics (brand and generic)
• β3-adrenergic agonists (growing preference in many markets)

What this means for brand pricing power

• Once competing agents are on formulary with comparable or better net pricing, brands lose pricing power rapidly.
• Enablex becomes a cost-sensitive alternative rather than a preferred option.

Key Takeaways

• Enablex (darifenacin) is in a mature, off-patent phase where market outcomes are driven less by patent exclusivity and more by generic substitution economics and formulary dynamics.
• Generic entry risk is structurally high for small-molecule oral drugs after core patent expiry; as generics proliferate, price compression typically dominates financial performance.
• Category-level competition from β3-adrenergic agonists and other bladder therapies reduces brand resilience, especially in payer-driven formularies.
• Financial trajectory follows a common pattern for legacy chronic oral brands: post-exclusivity revenue decline, margin erosion, then low-margin continuity based on contracting rather than IP moat.

FAQs

1. How quickly does Enablex lose market share after the first generic entry in the US?
2. Do formulation-specific patents for darifenacin meaningfully delay generic ANDA approvals?
3. What payer tactics most affect Enablex net price versus list price in overactive bladder?
4. How do clinical guideline updates shift prescribing away from antimuscarinics like darifenacin?
5. What are the main switch triggers for patients moving from Enablex to alternative OAB therapies?

References

(No citations provided in the user prompt; sources are required for an evidence-backed market/financial trajectory and patent/regulatory status analysis.)